LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Authors :: H.S. Rugo
A. Bardia
F. Marmé
J. Cortés
P. Schmid
D. Loirat
O. Tredan
E.M. Ciruelos
F. Dalenc
P. Gomez Pardo
K. Jhaveri
R.J. Delaney
T. Valdez
H. Wang
W. Verret
S.M. Tolaney
Source :: Annals of Oncology. 33:S1386
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Full Text Access

Tools